Obesity Is a Chronic Disease: From 5% Weight Loss to Medication and Surgery

Dr. Marco Ha · Author and medical reviewer

General, pediatric and trauma surgery · Last medically reviewed September 1, 2026

Editorial and sourcing policy

Why is obesity a chronic disease rather than simply eating too much?

The World Health Organization defines overweight and obesity as abnormal or excessive fat accumulation that presents a health risk. Food intake and activity matter, but they do not explain the whole disease. Brain appetite and reward pathways, gut hormones, adipose-tissue signals, genes, sleep, stress, illness, medication, shift work, food access and social conditions can all change weight.

After weight loss, biology may increase hunger, weaken fullness signals and reduce energy expenditure in an attempt to restore previous weight. This helps explain why short-term starvation diets commonly relapse. Follow-up, adaptation and relapse planning are therefore part of treatment, just as they are for hypertension or diabetes.

Which organs are affected, and what is CKM syndrome?

Excess visceral fat is associated with insulin resistance, chronic inflammation and abnormal fat deposition. It raises the risk of type 2 diabetes, hypertension, dyslipidemia, metabolic dysfunction-associated steatotic liver disease, obstructive sleep apnea, osteoarthritis, gallstones, heart attack, stroke and some cancers. Risk is not identical at the same weight, so fat distribution, laboratory results, blood pressure, function and existing disease all matter.

Cardiovascular-kidney-metabolic (CKM) syndrome describes the connected progression of obesity, diabetes, cardiovascular and kidney disease. The 2026 multidisciplinary AHA/ACC guideline places weight, blood pressure, lipids, glucose and kidney function in one prevention pathway so modifiable risk can be addressed before organ damage advances.

How does Taiwan classify adult BMI and waist size?

BMI cannot distinguish fat from muscle or show where fat is stored. It may overestimate risk in a very muscular person and underestimate sarcopenic obesity. Clinicians therefore combine BMI with waist, weight trajectory, blood pressure, blood tests, sleep, physical function and complications.

What do 5%, 10% and 15% weight-loss goals mean?

Five percent: an achievable, clinically meaningful first stage

At 90 kg, 5% is 4.5 kg. This amount may improve fasting glucose, blood pressure, triglycerides and liver fat for some people. It does not guarantee normalization or mean treatment is complete; it provides a practical first target instead of demanding an immediate “ideal BMI.”

Ten percent: broader disease and functional benefits often emerge

As weight loss increases, improvement in metabolic disease, fatty liver, sleep apnea, joint load and function often becomes more likely, although different conditions require different amounts. Track blood pressure, glucose, waist, liver markers, sleep and function alongside weight.

Fifteen percent or more: larger benefits are possible

In intensive weight-management studies of relatively early type 2 diabetes, larger weight loss was associated with a higher chance of remission. Remission means glucose remains below a defined threshold without glucose-lowering medication; it is not a cure or a guarantee at 15%, and diabetes duration, pancreatic function, medication and weight regain all influence the result.

What belongs in a medical weight-management assessment?

A useful assessment is more than a scale and a prescription. It reviews weight history, previous approaches, diet, activity, sleep and snoring, stress, mood, binge eating or other eating disorders, alcohol, smoking, pregnancy plans, chronic disease and medicines that may promote weight gain. Depending on the person, examination and testing may include waist, blood pressure, glucose or HbA1c, lipids, liver and kidney function, with targeted evaluation for thyroid disease, sleep apnea, fatty liver or other conditions.

Goals should also be personal: glucose improvement, lower anesthetic risk, better sleep, easier walking or preserved strength may take priority over a particular scale number. Those priorities influence medication, nutrition, exercise and referral for metabolic surgery.

A complete plan does not mean starvation

• Nutrition: create a sustainable energy deficit while protecting protein, produce, whole grains and essential micronutrients; carbohydrates and fat do not need to be eliminated.
• Physical activity: build aerobic movement to current ability and add resistance work to protect strength, bone and function.
• Sleep and stress: identify insufficient sleep, apnea, shift work and stress-related eating.
• Behavioral support: use measurable goals, identify triggers and plan for relapse; involve psychological care when indicated.
• Prescription medication: when indications and goals support it, medicine can begin alongside lifestyle care; a person need not prove moral worth by “failing” a starvation diet first.
• Metabolic surgery: selected higher-risk patients may achieve larger and more durable metabolic benefit, balanced against operative risk and lifelong nutritional follow-up.

Who may discuss anti-obesity medication with a clinician?

Taiwan classifies adult BMI 27 or above as obesity, but a disease threshold is not the same as a product's prescribing indication. A common adult chronic-weight-management label uses:

• BMI ≥30 kg/m²; or
• BMI ≥27 kg/m² with at least one weight-related condition, such as type 2 diabetes, hypertension, dyslipidemia or obstructive sleep apnea, as specified in the particular label.

The active ingredient, brand, age and current Taiwan approval govern eligibility. Central obesity alone or a wish for rapid cosmetic loss does not automatically justify medicine. Conversely, when risk is clear, current EASO 2025 and ADA 2026 guidance supports choosing treatment according to complications rather than treating pharmacotherapy only as a last resort.

How much weight do different medicines reduce on average?

The table uses representative trial averages to show scale, not rank. Populations, diabetes status, lifestyle programs, doses, completion and analysis differed. Results across separate trials cannot be compared as if they were head-to-head and do not predict an individual's outcome.

Which medication safety checks must not be skipped?

• Legitimate prescription: injectable and oral prescription weight-loss medicines require medical assessment and pharmacist dispensing. Avoid unverified online, repackaged or “same ingredient” products.
• Pregnancy: weight loss is not a treatment goal during pregnancy. Discuss pregnancy plans early and follow the product-specific stopping interval.
• Pancreas and gallbladder: persistent or severe upper-abdominal pain, pain to the back, repeated vomiting, fever or jaundice needs prompt assessment.
• Dehydration and kidneys: repeated vomiting or diarrhea, inability to drink, markedly reduced urine, dizziness or weakness should not simply be endured.
• Hypoglycemia: GLP-1-based treatment alone has a low hypoglycemia risk, but insulin or a sulfonylurea may need adjustment.
• Surgery and anesthesia: altered gastric emptying matters for aspiration risk. Tell the procedural and anesthesia teams; they decide any medication adjustment.

Insufficient response, a plateau or regain after stopping does not represent personal failure. Clinicians reassess tolerability, adherence, sleep, comorbidity, weight-promoting medication, nutrition and movement before continuing, changing or escalating care.

When should metabolic and bariatric surgery be assessed?

Metabolic surgery is not liposuction and is not simply “making the stomach smaller.” Procedures such as sleeve gastrectomy and Roux-en-Y gastric bypass affect intake, gastrointestinal hormones and metabolism. International ASMBS/IFSO guidance recommends assessment at BMI ≥35 and consideration at BMI 30–34.9 with metabolic disease or inadequate durable improvement from nonsurgical care; population-specific thresholds may be lower for Asian patients.

International recommendations do not necessarily equal Taiwan hospital entry or insurance coverage rules. A real decision integrates complications, previous treatment, anesthetic and surgical risk, nutrition, eating behavior, psychological health and ability to complete lifelong supplementation and follow-up. Surgery can deliver substantial benefit but carries risks including bleeding, leak, thrombosis, gallstones, reflux, nutritional deficiency and further intervention.

How sources are selected, reviewed and corrected: Medical editorial and sourcing policy.